| Name |
STf Antigen: Fmoc-Ser(Neu5Acα(2-3)Galβ(1-3)GalNAc)-OH (Peracetate, Benzyl Ester)
|
|---|
| Product No. | GA121020 |
|---|
| Synonym(s) |
STf Epitope (Serine); STf Antigen (Serine); ST Antigen; Sialyl-T Antigen; Fmoc-L-Ser(Neu5Acα(2-3)Galβ(1-3)GalNAc)-OH (Peracetate, Benzyl Ester); Fmoc-Ser(α-L-Neu5Ac(Ac)₄-(2-3)-β-D-Gal(Ac)₃-(1-3)-α-D-GalNAc(Ac)₂)-OH
|
|---|
| Category | Glycoamino AcidsSerine |
|---|
| Formula | C62H77N3O32 |
|---|
| Molecular Weight | 1376.28 |
|---|
| Availability | No - Please inquire for availability information |
|---|
| Availability in Bulk | Yes |
|---|
| Purity | >90% (HPLC) |
|---|
| Description | Tumor-Associated Carbohydrate Antigen (TACA). STF-antigen (also ST) is a sialylated form of the truncated O-glycosylated core determinant TF (also T) with structure: Neu5Acα2-3Galβ1-3GalNAcα-O-Ser/Thr. STF results from an early sialylation of the TF antigen due to overexpression of the enzyme α2,3sialylT and/or disruption of further glycan elongation processes. STF is negligibly expressed in healthy tissues but overexpressed in human carcinomas . As such, STF is implicated in tumour cell organotropic metastasis. Targeting immune responses to truncated variants of O-glycan chains expressed by tumour cells represents a promising approach for the development of antigen-specific therapeutic vaccines against cancers, and accumulated evidence has rendered STF a prime target for cancer immunotherapy. |
|---|
| Comments | N-Acetyl-D-Galactosamine; O-Link; Trisaccharide; Serine; Blocked; Amino Acid; Ac, Me |
|---|
